Hepion Pharmaceuticals, Inc.

NasdaqCM:HEPA Voorraadrapport

Marktkapitalisatie: US$3.8m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Hepion Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

John Brancaccio

Algemeen directeur

US$81.0k

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOless than a year
Eigendom CEO0.006%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur2yrs

Recente managementupdates

Recent updates

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

Aug 10
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Apr 25
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Oct 27
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharma rises as company begins NASH treatment trial

Aug 31

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Jul 04
Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Feb 17

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Jan 21

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Sep 21

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Sep 14
Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Sep 08

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

May 26

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Feb 18
What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Hepion Pharma cleared to advance final dosing cohort in NASH trial

Dec 29

Hepion Pharma to begin CRV431 testing in COVID-19 patients

Dec 22

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Dec 10

Hepion Pharma prices equity offering at $1.50

Nov 25

Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow

Oct 31

CEO

John Brancaccio (76 yo)

less than a year

Tenure

US$81,000

Compensatie

Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June...

Bestuursleden

NaamPositieTenureCompensatieEigendom
John Brancaccio
Interim CEO11.4yrsUS$81.00k0.0060%
$ 229.8
Timothy M. Block
Independent Director10.9yrsUS$72.90k0.0060%
$ 229.8
Vlad Ratziu
Member of Scientific Advisory Board1.6yrsgeen gegevensgeen gegevens
Rohit Loomba
Member of Scientific Advisory Board1.6yrsgeen gegevensgeen gegevens
Stephen A. Harrison
Scientific Advisory Board Chair5.2yrsgeen gegevensgeen gegevens
Nikolai Naoumov
Member of Scientific Advisory Board1.6yrsgeen gegevensgeen gegevens
Philippe Gallay
Member of Scientific Advisory Board8.3yrsgeen gegevensgeen gegevens
Michael Purcell
Independent Directorless than a yeargeen gegevensgeen gegevens
Yury Popov
Member of Scientific Advisory Board1.6yrsgeen gegevensgeen gegevens
Kaouthar Lbiati
Independent Director2.3yrsUS$80.50kgeen gegevens

2.0yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HEPA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw bestuur.